Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $12.75.

LUNG has been the subject of a number of recent research reports. Morgan Stanley began coverage on shares of Pulmonx in a report on Monday, March 10th. They set an "equal weight" rating on the stock. Citigroup started coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a "buy" rating on the stock. D. Boral Capital began coverage on Pulmonx in a research note on Monday, March 10th. They set a "buy" rating and a $17.00 price target for the company. Finally, Jefferies Financial Group assumed coverage on Pulmonx in a report on Monday, March 10th. They set a "buy" rating for the company.

Pulmonx Stock Up 0.6 %

Shares of LUNG stock traded up $0.03 on Tuesday, reaching $5.20. 239,817 shares of the company were exchanged, compared to its average volume of 317,235. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The company has a 50-day moving average of $6.81 and a 200-day moving average of $6.60. The company has a market cap of $209.28 million, a price-to-earnings ratio of -3.61 and a beta of 0.61. Pulmonx has a one year low of $4.15 and a one year high of $10.01.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.12. The business had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. Analysts anticipate that Pulmonx will post -1.55 earnings per share for the current year.

Insider Buying and Selling at Pulmonx

In related news, CFO Mehul Joshi sold 14,384 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.12, for a total transaction of $102,414.08. Following the completion of the transaction, the chief financial officer now owns 113,986 shares in the company, valued at approximately $811,580.32. This represents a 11.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Glendon E. French III sold 55,453 shares of Pulmonx stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $8.28, for a total transaction of $459,150.84. Following the completion of the sale, the director now directly owns 1,011,974 shares in the company, valued at approximately $8,379,144.72. This represents a 5.20 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 145,660 shares of company stock worth $1,128,484. Insiders own 6.80% of the company's stock.

Institutional Investors Weigh In On Pulmonx

Hedge funds have recently modified their holdings of the stock. Barclays PLC increased its position in Pulmonx by 1.8% in the third quarter. Barclays PLC now owns 94,109 shares of the company's stock worth $780,000 after buying an additional 1,679 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Pulmonx by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company's stock worth $2,142,000 after acquiring an additional 2,363 shares during the last quarter. Rhumbline Advisers raised its stake in Pulmonx by 4.6% in the 1st quarter. Rhumbline Advisers now owns 55,958 shares of the company's stock valued at $377,000 after acquiring an additional 2,455 shares during the period. American Century Companies Inc. lifted its holdings in Pulmonx by 8.8% during the fourth quarter. American Century Companies Inc. now owns 34,738 shares of the company's stock valued at $236,000 after purchasing an additional 2,810 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock worth $106,000 after purchasing an additional 3,310 shares during the period. Institutional investors own 91.04% of the company's stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.